You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 7,498,343

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,498,343 protect, and when does it expire?

Patent 7,498,343 protects SIRTURO and is included in one NDA.

This patent has fifty-seven patent family members in thirty-five countries.

Summary for Patent: 7,498,343

Title:	Mycobacterial inhibitors
Abstract:	The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or the general Formula (Ib) ##STR00001## the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. The claimed compounds are useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as Mycobacterium tuberculosis, M. bovis, M. avium and M. marinum. In particular, compounds are claimed in which, independently from each other, R.sup.1 is bromo, p=1, R.sup.2 is alkyloxy, R.sup.3 is optionally substituted naphthyl or phenyl, q=1, R.sup.4 and R.sup.5 each independently are hydrogen, methyl or ethyl, R.sup.6 is hydrogen, r is equal to 0 or 1 and R.sup.7 is hydrogen. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of mycobacterial diseases and a process for preparing the claimed compounds.
Inventor(s):	Van Gestel; Jozef Frans Elisabetha (Beerse, BE), Guillemont; Jerome Emile Georges (Val de Reuil Cedex, FR), Venet; Marc Gaston (Le Mans, FR), Poignet; Herve Jean Joseph (Issy-les-Moulineaux Cedex 9, FR), Decrane; Laurence Francoise Bernadette (Val de Reuil Cedex, FR), Vernier; Daniel F. J. (Val de Reuil Cedex, FR), Odds; Frank Christopher (Drumoak, GB)
Assignee:	Janssen Pharmaceutica N.V. (Beerse, BE)
Application Number:	11/007,026
Patent Claim Types: see list of patent claims	Compound; Composition; Use; Process;
Patent landscape, scope, and claims:	United States Patent 7,498,343: A Detailed Analysis of Scope, Claims, and Patent Landscape Introduction United States Patent 7,498,343, titled "Mycobacterial inhibitors," is a significant patent in the pharmaceutical sector, particularly in the treatment of mycobacterial diseases. This patent, assigned to MedCo, involves novel substituted quinoline derivatives and their application in medical treatments. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention. Patent Overview Title and Abstract The patent titled "Mycobacterial inhibitors" describes novel substituted quinoline derivatives according to a specific formula. These compounds are designed for the treatment of mycobacterial diseases, particularly those caused by pathogenic mycobacteria[4][5]. Inventors and Assignees The patent was assigned to MedCo, with the inventors not specified in the sources provided but typically listed in the patent document itself. Patent Number and Dates The patent number is US 7,498,343, and it was issued on a date that can be found in the patent document details, although the exact issue date is not provided in the sources. Scope of the Patent Claims The patent includes claims directed to the preparation and use of the novel substituted quinoline derivatives. These claims are crucial as they define the scope of the invention and what is protected under the patent. The claims typically include: Composition of Matter Claims: These claims cover the specific chemical compounds and their formulations. Method of Use Claims: These claims cover the methods of using the compounds for treating mycobacterial diseases. Process Claims: These might include the methods of synthesizing the compounds[4][5]. Patent Scope Metrics The scope of a patent can be measured using metrics such as independent claim length (ICL) and independent claim count (ICC). These metrics help in understanding the breadth and clarity of the patent claims. Narrower claims, as indicated by shorter ICL and lower ICC, are often associated with a higher probability of grant and a shorter examination process[3]. Claims Analysis Independent Claims Independent claims are the foundation of a patent as they define the invention without reference to other claims. For US 7,498,343, the independent claims would specify the novel quinoline derivatives and their uses. These claims are critical in determining the patent's scope and validity. Dependent Claims Dependent claims build upon the independent claims and provide additional details or limitations. They help in further defining the invention and can offer additional protection by covering various aspects of the invention. Patent Landscape Related Patents The patent landscape for mycobacterial inhibitors includes other related patents that may cover similar or complementary inventions. For example, other patents might cover different compounds or methods for treating mycobacterial diseases. Understanding these related patents is essential for navigating potential infringement issues and identifying opportunities for innovation[2]. Exclusivity and Patent Expiration The patent US 7,498,343 is set to expire on December 1, 2026, assuming it was filed 20 years prior to this date. This expiration date marks the end of MedCo's exclusive rights to the invention, after which the technology will enter the public domain. Additionally, any drug exclusivity granted by the FDA may run concurrently with the patent term but can vary in duration[2]. On-Sale Bar and Commercial Transactions An important aspect of patent law relevant to this patent is the on-sale bar under 35 U.S.C. §102(b). This provision invalidates a patent if the invention was on sale more than one year before the patent application was filed. In the case of MedCo's transactions with Ben Venue for the manufacture of bivalirudin (another drug), the Federal Circuit held that there was no commercial sale because MedCo retained ownership of the invention and only purchased manufacturing services. This decision supports the practice of using third-party contract manufacturing services without triggering the on-sale bar[1]. Industry Impact Pharmaceutical Development The patent US 7,498,343 is significant in the pharmaceutical industry as it protects novel compounds for treating mycobacterial diseases. This protection encourages innovation by allowing the patent holder to recoup investment in research and development. The use of contract manufacturing services, as validated by the Federal Circuit, also facilitates the development process by enabling companies to outsource manufacturing while retaining control over the invention[1]. Competitive Landscape The patent landscape in the pharmaceutical sector is highly competitive, with multiple companies developing treatments for similar diseases. The validity and scope of patents like US 7,498,343 are crucial in this competitive environment, as they determine the boundaries of what is protected and what is open for innovation. Key Takeaways Patent Scope: The patent US 7,498,343 covers novel substituted quinoline derivatives for treating mycobacterial diseases. Claims Analysis: Independent and dependent claims define the invention and its scope. Patent Landscape: The patent is part of a broader landscape that includes related patents and exclusivity periods. On-Sale Bar: The patent is not affected by the on-sale bar due to the nature of contract manufacturing agreements. Industry Impact: The patent is significant for pharmaceutical development and the competitive landscape. FAQs What is the main subject of United States Patent 7,498,343? The main subject of United States Patent 7,498,343 is novel substituted quinoline derivatives used for treating mycobacterial diseases. Who is the assignee of the patent? The assignee of the patent is MedCo. When is the patent set to expire? The patent is set to expire on December 1, 2026. What is the significance of the on-sale bar in this context? The on-sale bar is significant because it determines whether a patent is invalid if the invention was commercially sold more than one year before the patent application was filed. However, in this case, the Federal Circuit ruled that contract manufacturing agreements do not trigger the on-sale bar. How does the patent impact the pharmaceutical industry? The patent protects novel compounds, encouraging innovation and allowing the patent holder to recoup investment in research and development. It also validates the use of contract manufacturing services without triggering the on-sale bar. What metrics can be used to measure the scope of a patent? Metrics such as independent claim length (ICL) and independent claim count (ICC) can be used to measure the scope and clarity of patent claims. Sources Banner Witcoff, IP Alert: Full Federal Circuit Affirms District Court on Inapplicability of On-Sale Bar to MedCo’s Transactions, July 11, 2016. Drugs.com, Generic Sirturo Availability, November 6, 2024. Hoover Institution, Patent Claims and Patent Scope, August 18, 2024. Google Patents, US7498343B2 - Mycobacterial inhibitors, Retrieved 2024. DrugPatentWatch, Details for Patent: 7498343, Retrieved 2024. More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 7,498,343

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Janssen Therap	SIRTURO	bedaquiline fumarate	TABLET;ORAL	204384-002	May 27, 2020		RX	Yes	No	7,498,343	⤷ Subscribe	Y	Y		TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS	⤷ Subscribe
Janssen Therap	SIRTURO	bedaquiline fumarate	TABLET;ORAL	204384-001	Dec 28, 2012		RX	Yes	Yes	7,498,343	⤷ Subscribe	Y	Y		TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 7,498,343

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1527050	⤷ Subscribe	C300684	Netherlands	⤷ Subscribe
European Patent Office	1527050	⤷ Subscribe	PA2014032	Lithuania	⤷ Subscribe
European Patent Office	1527050	⤷ Subscribe	CA 2014 00044	Denmark	⤷ Subscribe
European Patent Office	1527050	⤷ Subscribe	C20140026 00112	Estonia	⤷ Subscribe
European Patent Office	1527050	⤷ Subscribe	1490050-0	Sweden	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.